Table 2 Treatment-related adverse events
All grades | Grade 3 or worse | |
---|---|---|
Any events, n (%) | 37 (97.4) | 20 (52.6) |
Frequent events, n (%) | ||
Aspartate aminotransferase increased | 28 (73.7) | 13 (34.2) |
Alanine aminotransferase increased | 25 (65.8) | 7 (18.4) |
White blood cell decreased | 16 (42.1) | 0 |
Platelet count decreased | 15 (39.5) | 6 (15.8) |
Neutrophil count decreased | 15 (39.5) | 1 (2.6) |
Gastrointestinal bleeding | 16 (42.1) | 1 (2.6) |
Thyroid stimulating hormone increased | 14 (36.8) | 0 |
Hypoalbuminemia | 11 (28.9) | 0 |
Endocrine disorders | 8 (21.1) | 0 |
Weight loss | 7 (18.4) | 0 |
Blood bilirubin increased | 5 (13.2) | 0 |
Rash | 5 (13.2) | 0 |
Hypothyroidism | 6 (15.8) | 0 |
Hyperthyroidism | 4 (10.5) | 0 |
Palmar-plantar erythrodysesthesia syndrome | 3 (7.9) | 2 (5.3) |
Hypertension | 2 (5.3) | 1 (2.6) |
Hypertriglyceridemia | 1 (2.6) | 1 (2.6) |